CESAR, Saladax begin patient enrollment in paclitaxel CEPAC-TDM trial for NSCLC

[News]

In collaboration with Saladax Biomedical, Inc., the Central European Society for Anticancer Drug Research announced today that enrollment has begun in the CEPAC-TDM trial of paclitaxel therapeutic drug management with subsequent pharmacokinetic-guided dose adjustment in patients being treated for advanced non-small cell lung cancer.

More... (http://www.news-medical.net/news/20110427/CESAR-Saladax-begin-patient-enrollment-in-paclitaxel-CEPAC-TDM-trial-for-NSCLC.aspx)